Pulmonary tuberculosis
ICD-10 A15.0 ICD-11 1B10

Treatment of Non-Severe Pulmonary TB in Children Aged 3 Months to 16 Years

This protocol covers pulmonary tuberculosis in children and adolescents aged 3 months to 16 years who present with non-severe disease and no suspicion or evidence of multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB).

Clinical Scenario

Non-severe pulmonary TB in this age group is defined as disease confined to one lobe with no cavities and no miliary pattern, intrathoracic lymph node TB without airway obstruction, or an uncomplicated pleural effusion — in a child weighing more than 3 kg, without MDR/RR-TB.

Treatment Approach

Management centres on a 4-month oral anti-tuberculosis regimen incorporating isoniazid and rifampicin together with other agents in the initial phase. Whether additional agents are required depends on specific epidemiological and clinical circumstances.

The complete regimen — including phase structure, agent combinations, and setting-specific modifications — is available in the full protocol.

Treatment Goals

TB symptoms are expected to resolve within one month of starting treatment. Demonstrable weight gain and symptomatic improvement are the most valuable markers of response. After 4 months of treatment, the child should be completely well with a normal nutritional status.

Instant Access to Structured Evidence-Based Regimens

References

  1. In children and adolescents between 3 months and 16 years of age with non-severe TB (without suspicion or evidence of MDR/RR-TB), a 4-month treatment regimen (2HRZ(E)/2HR) should be used.
  2. All patients weighing more than 3 kg and aged between 3 months and 16 years, with non-severe TB based on the definition presented in Box 2.1, should be treated with the 4-month regimen 2HRZ(E)/2HR, with or without ethambutol.
  3. Children and adolescents aged between 3 months and 16 years with non-severe DS-TB should receive the 4-month regimen 2HRZ(E)/2HR, which comprises isoniazid, rifampicin and pyrazinamide, with or without ethambutol, for 2 months followed by isoniazid and rifampicin for 2 months.
  4. In addition, it is recommended that ethambutol be added to the 4-month regimen for the first 2 months in settings with a high background prevalence of isoniazid resistance or HIV infection.
  5. TB symptoms are expected to have resolved within one month of treatment initiation.
  6. The child or adolescent is expected to be completely well, including a normal nutritional status (similar to before they developed symptoms of TB) after 4 months of treatment.
  7. Symptomatic improvement and weight gain are the most valuable markers of treatment success or failure.
View source ↗